Drug Discovery

Europe’s largest initiative launches to accelerate therapy development for Covid-19

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19.

BOLD-100 significantly outperforms remdesivir head-to-head in SARS-CoV-2 model

Bold Therapeutics, a clinical-stage biopharmaceutical company, recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral.

BMS signs $475m deal with Dragonfly Therapeutics for IL-12 programme

Bristol Myers Squibb (BMS) has agreed to acquire the global exclusive licensing rights to interleukin-12 (IL-12), an investigational immunotherapy programme from Dragonfly Therapeutics, in a deal worth more than $475m.

Gilead, Tango expand collaboration on targeted immuno-oncology treatments

Biopharmaceutical company Gilead Sciences has expanded its strategic oncology collaboration with biotechnology company Tango Therapeutics.

New Edition of NSF’s Health Sciences Journal Now Live

This edition of the health sciences Journal is about hope and optimism, and how we must rethink our ways of working.

Sanofi to buy biopharmaceutical firm Principia Biopharma for $3.68bn

French drugmaker Sanofi has agreed to acquire late-stage biopharmaceutical company Principia Biopharma for an aggregate equity value of around $3.68bn.

UNION therapeutics to acquire licence for Covid-19 technologies developed by TFF Pharmaceuticals

UNION therapeutics announced the completion of an agreement with TFF Pharmaceuticals (TFF) to acquire an option to obtain a worldwide exclusive license for the use of their Thin Film Freezing technology in combination with niclosamide to focus on treatments for COVID-19.

GeneCentric, Janssen collaborate to study genomic drug response biomarkers for NMIBC

GeneCentric Therapeutics has announced a research collaboration with Janssen Research & Development on RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC).

Bayer to buy UK biotech company KaNDy Therapeutics

Bayer has agreed to acquire UK-based clinical-stage biotech company KaNDy Therapeutics for an upfront consideration of $425m.